Rear Obtained FDA approval In order to improve the attention game of children with ADHD, digital health company Akili Interactive is looking to bring another product to the market.
The Boston-based company has reached a $37.5 million license agreement with Australian digital health company TALi Digital to bring its game-based therapy to the United States
Similar to Akili’s first product, TALi’s digital therapy focuses on improving children’s concentration. Tablet-based games are designed to improve children’s selective attention, or the ability to focus on important information while ignoring distractions. It is currently listed in Australia, India, Singapore and Hong Kong and is currently not related to specific indications.
Although the two companies have adopted a similar approach, TALi’s games are aimed at younger people. Akili’s games are allowed for children from 8 to 12 years old, while TALi’s games are designed for children from 3 to 8 years old.
“Focusing on attention-oriented early childhood interventions, TALi’s impressive technology is an ideal addition to Akili’s product portfolio. We are committed to changing people’s perceptions of medicine, and strategic agreements like this will allow us to expand our Vision, treat cognitive impairment in a new way, and usher in the next generation of digital therapy,” Akili CEO Eddie Martucci said in a statement. Press Releases.
Akili plans to use its recent experience to conduct clinical trials on TALi’s children’s ADHD technology, with the goal of obtaining FDA approval for this indication. According to the agreement with TALi, it will be responsible for commercialization.
The $37.5 million list price includes milestone payments and royalties on potential revenue.
Photo credit: maxsattana, Getty Images
